Kim M. Hirshfield

Articles by Kim M. Hirshfield

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

BySara M. Tolaney, MD, MPH,Paolo D’Amico,Liyi Jia,Kim M. Hirshfield,Fatima Cardoso

April 16th 2025

Latest Updated Articles

Trending on CancerNetwork

No New Safety Signals Seen With V940 Plus Pembrolizumab in Melanoma

Signatera ctDNA Test Shows Superior MRD Assessment in Lymphoma

How Is AI Shaping Patient-Centered, Multidisciplinary Oncology Care?

Savolitinib Combo Boosts PFS in First-Line EGFR-Mutant NSCLC Trial

FDA Receives sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis